Description de l'entreprise
Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retina diseases including all stages of age-related macular degeneration.
Conseil d'administration & Conseil de surveillance
| PDG |
| Glenn P. Sblendorio |
| Conseil d'administration |
| David F. Carroll, Keith Westby, Pravin U. Dugel |
| Conseil de surveillance |
| Adrienne L. Graves, Axel Bolte, Calvin Roberts, Glenn P. Sblendorio, Jane Pritchett Henderson, Mark S. Blumenkranz |
Données de l'entreprise
| Nom: |
Iveric Bio Inc. |
| Adresse: |
Five Penn Plaza, Suite 2372,New York, NY 10001, USA |
| Téléphone: |
+1-212-845-8200 |
| Fax: |
- |
| Courriel: |
info@ivericbio.com
|
| Internet: |
https://ivericbio.com/ |
| Industrie: |
Biotechnology |
| Secteur: |
Biotechnology |
| Sous-secteur: |
Biotechnology |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
- |
| IPO date: |
16/12/2016 |
